Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
The industry’s first ALK degrader starts its first human study.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
